Teva halts tests of cancer drug biosimilar

The pharmaceutical giant has suspended third-phase testing of its generic version of the $7 billion a year drug Rituxan, used in the treatment of cancer and rheumatoid arthritis.

By Yoram Gabison | 09:02 04.10.12 |

Text size

this story is by

Yoram Gabison

related tags

Israel drugs

Israel stock market

Teva Pharmaceutical Industries has suspended testing of its generic version of Rituxan, a $7-billion a year drug, at the third stage of clinical trials.

The full text is available for subscribers & registered users.

Click here to subscribe ($1 for the first 4 weeks)
register (free access for 10 stories a month) or

comments

thank you

Your talkback has been submitted successfully.
If selected for publication, it will appear as soon as possible on Haaretz.com.

Reply again

Haaretz Select

If only I'd known: Motherhood is an identity holocaust

Roni Halpern loves her children but is not sure she would have had them if she'd known then what she knows now and has written about in her new book, 'Body and its Discontents.'

By Maya Sela | Weekend | 2

Uncovering history in the Jordan Valley, with the help of National Geographic

By Nir Hasson | Weekend

'If the settlement of Elon Moreh wasn't here, we'd be living in paradise'

By Gideon Levy, Alex Levac | Twilight Zone | 2

Plans for the Israeli summer break: Drama? Crisis? War?

By Doron Rosenblum | Doron Rosenblum

Departures / Arrivals: Hadas bids farewell to Tel Aviv with a one-way ticket

Rizin is not sure about living in Munich, but getting his German girlfriend to move to Jerusalem is equally challenging.

By Liat Elkayam | Departures/Arrivals

Meat and greet: Art festival reaches the Arab Galilee

By Shany Littman | Magazine

Why Shalom Auslander left me hopeful, after all

By Neri Livneh | Neri Livneh

Catastrophic thinking: Did Ben-Gurion try to rewrite history?

By Shay Hazkani | Magazine | 82

Business

Experts warn: Economy unsustainable if Haredim and Arabs don't join workforce

By Meirav Arlosoroff | 02:00 AM

How did Israel reach a NIS 40 billion budget deficit?

By Hagai Amit | 07:02 PM | 8

Tech roundup / Stymieing smartphone smugglers

By Ruth Schuster | 10:32 AM

Market Report / Technology shares, Teva pull TASE higher

By Eran Azran | 04:38 AM

Facebook

Activity
Recommendations

Teva halts tests of cancer drug biosimilar

The pharmaceutical giant has suspended third-phase testing of its generic version of the $7 billion a year drug Rituxan, used in the treatment of cancer and rheumatoid arthritis.

REPLY TO THIS TALKBACK